Back to top
more

Clovis Oncology, Inc. (CLVS)

(Delayed Data from NSDQ)

$18.95 USD

18.95
1,240,915

+0.51 (2.77%)

Updated May 3, 2019 04:00 PM ET

After-Market: $18.96 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Onconova (ONTX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will watch for updates on its lead candidate narazaciclib when Onconova Therapeutics. (ONTX) reports first-quarter earnings.

Viatris (VTRS) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Viatris' (VTRS) Q1 earnings might have been adversely impacted by competition in the complex generics business.

Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 0% and 45.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Will Eylea, Dupixent Buoy Regeneron's (REGN) Q1 Earnings?

by Zacks Equity Research

Regeneron's (REGN) first-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent.

Is a Beat in Store for Zoetis (ZTS) This Earnings Season?

by Zacks Equity Research

Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases first-quarter 2022 results.

DaVita (DVA) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Supply shortage along with pandemic-led incremental mortality rate is likely to have weighed on DaVita's (DVA) first-quarter top line.

Clovis Oncology (CLVS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Clovis (CLVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Clovis (CLVS) Up 24% on Upbeat Data From Ovarian Cancer Study

by Zacks Equity Research

Clovis Oncology's (CLVS) stock price rises after it reports favorable data from a late-stage study on Rubraca as the first-line maintenance treatment of ovarian cancer.

Why Is Clovis (CLVS) Down 14.8% Since Last Earnings Report?

by Zacks Equity Research

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AstraZeneca, Merck's Lynparza Cut Risk of Breast Cancer Death

by Zacks Equity Research

Treatment with AstraZeneca (AZN) and Merck's (MRK) Lynparza show meaningful improvement in overall survival for patients with BRCA-mutated HER2-negative high-risk early breast cancer.

AstraZeneca, Merck's Lynparza Gets FDA Nod for Expanded Use

by Zacks Equity Research

FDA approves AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.

Clovis (CLVS) Q4 Loss Narrower than Expected, Revenues Lag

by Zacks Equity Research

Clovis (CLVS) reports narrower-than-expected loss for fourth-quarter 2021. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.

Drug/Biotech Stocks' Q4 Earnings on Feb 23: BMRN, BHC & More

by Zacks Equity Research

Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.

Is the Options Market Predicting a Spike in Clovis Oncology (CLVS) Stock?

by Zacks Equity Research

Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.

Why Is Clovis (CLVS) Down 32% Since Last Earnings Report?

by Zacks Equity Research

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AstraZeneca, Merck's Lynparza sNDA Gets FDA Priority Tag

by Zacks Equity Research

FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) sNDA for Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.

Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Lag

by Zacks Equity Research

Clovis (CLVS) reports wider-than-expected loss for third-quarter 2021. Sales of the company's sole marketed drug, Rubraca, declined year over year owing to COVID-19 impacts.

Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Clovis (CLVS) delivered earnings and revenue surprises of -16.67% and -2.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Clovis Oncology (CLVS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Clovis (CLVS) Focuses on Rubraca Growth Amid Rising Competition

by Zacks Equity Research

Clovis Oncology's (CLVS) sole marketed drug Rubraca has been approved for multiple cancer indications. Yet, the drug's sales remain tepid on account of competition from PARP inhibitors.

Sanghamitra Saha headshot

Bet on Rising P/E Investing With These Top 5 Stocks

by Sanghamitra Saha

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Clovis (CLVS) Down 3.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Clovis (CLVS) Q2 Earnings Miss, PARP Drug Rubraca Sales Down

by Zacks Equity Research

Clovis (CLVS) reports wider-than-expected loss for second-quarter 2021. Sales of the company's sole marketed drug, Rubraca, decreased year over year due to COVID-19 impacts.

Clovis Oncology (CLVS) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Clovis (CLVS) delivered earnings and revenue surprises of -7.02% and -9.78%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.